OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
OKYO Pharma Limited has announced that its Executive Chairman, Gabriele Cerrone, through Panetta Partners Limited, has increased his stake in the company by purchasing 50,000 additional shares at $1.05 each, now holding 28.73% of the issued share capital. The biopharmaceutical company is advancing in the clinical development of OK-101, a novel treatment for dry eye disease and neuropathic corneal pain, recently completing a successful Phase 2 trial for dry eye disease with plans to initiate a Phase 2 trial for treating corneal pain.
For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.
